AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06328946 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasogastric Tube Feeding
Description: The control group was given enteral nutritional support with Nasogastric Tube Feeding according to the relevant guidelines. Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient\&#39;s cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements. The feeding content was formulated by the nutritionists based on the patient\&#39;s condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups. For patients with limited tube feeding compliance, we made appropriate adjustments to ensure that they were not at risk of severe malnutrition as much as possible.
Study NCT06185400 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disitamab Vedotin
Description: RC48+third-generation EGFR TKIs (Almonertinib/Furmonertinib/Osimertinib) in treatment naive NSCLC
Study NCT06185400 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: third-generation EGFR TKIs (Almonertinib/Furmonertinib/Osimertinib)
Description: RC48+third-generation EGFR TKIs (Almonertinib/Furmonertinib/Osimertinib) after EGFR-TKIs progression
Study NCT06185400 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pyrotinib
Description: RC48+pyrotinib after EGFR-TKIs progression
Study NCT05453864 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CMAP Plus TFCBT
Description: This will include 8 individual sessions of CMAP Plus TFCBT delivered by a trained therapist over a period of 12 weeks. Each session will last between 45 to 60 minutes.
Study NCT05506709 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Seawater nasal spray
Description: Subjects will use the nasal spray (moderately hypertonic solution based on 100% natural sea water rich of marine trace elements with added manganese and calcium) at least once and up to 6 times as necessary per day during the 14-day test period. Each application is composed of two irrigating sprays per nostril for a total of 4 sprays per application.
Study NCT06157853 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Sunscreen
Description: Bland sunscreen to be used by subjects after cleansing and the facial moisturizer during the 7-day washout period. Bland sunscreen to be used by subjects after cleansing and after the active post-procedure cream and comparator anhydrous cream. Use the provided sunscreen and reapply as needed throughout the day and per recommendation of the FDA, every 2 hours.
Study NCT06080373 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PROBECO
Description: Spanish participants in the active control group will undergo the PROBECO program, designed by the Spanish Penitentiary Agency for various violent crimes. It aims to eradicate criminal behavior, reduce recidivism, and teach social skills. It has four phases.~German participants will be placed in social therapeutic facilities for compulsory psychotherapy focused on relapse prevention.
Study NCT06080373 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Formulation-based cognitive behavioral therapy
Description: The CBT program includes these core modules:~A. ADHD Psychoeducation: Provides information on ADHD characteristics, neurobiology, treatments, and their efficacy. Shared with a significant other if available.~B. Planning Skills and Distraction Management: Teaches time management, task prioritization, and distraction control techniques.~C. Cognitive Restructuring: Based on Ellis' Rational Behavioral Emotive Therapy, it helps participants identify and modify irrational thoughts for better emotional regulation.~D. Maintenance of Treatment Gains: Reviews progress, identifies risk factors, and develops action plans for post-treatment challenges.
Study NCT06027112 — intervention group
Intervention type: OTHER
Intervention: musculoskeletal injuries
Description: This research will be conducted to identify the factors that increase the risk of musculoskeletal injuries in university students,
Study NCT05542953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]APN-1607
Description: In this study, all patients will receive one injection of \[18F\]APN-1607, a PET radiopharmaceutical selective for fibrillar tau. For the injection, subjects will receive a target dose of 5-7 mCi IV as a bolus injection. \[18F\]APN-1607 injection will be followed by a 10 ml saline flush.
Study NCT04124263 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational short message texts
Description: Educational messages for patient engagement
Study NCT04124263 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adherence short message texts
Description: Reminder messages of medication use time
Study NCT05301400 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bti Unit
Description: Comparison with or without the device
Study NCT05585567 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V-01/V-01-B5
Description: Contains 10μg of V-01 and 10μg of V-01-B5
Study NCT05585567 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V-01-351/V-01-B5
Description: Contains 10μg of V-01-351 and 10μg of V-01-B5
Study NCT05585567 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V-01
Description: Contains 10μg of V-01
Study NCT06271200 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intermittent fasting and 10,000 steps per day
Description: Reduce calories intake and eat as 168 pattern, namely, eating foods for 8 hours while fast for 16 hours at daily basis plus walking more than 10,000 steps per day.
Study NCT05864924 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cohort A: 3.0x10^6 CAR-T cells/kg
Description: Intravenous infusion
Study NCT05864924 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cohort B: 9.0x10^6CAR-T cells/kg
Description: Intravenous infusion
Study NCT05864924 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cohort C:1.5x10^7 CAR-T cells /kg
Description: Intravenous infusion
Study NCT05322863 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High-definition Transcranial Direct Current Stimulation
Description: The HD-tDCS will be administered by the program device called Starstim (Neuroelectrics). All participants will receive the treatment by using the same model of device. The HD-tDCS device can be portable and controlled wirelessly via computer software developed by the manufacturer. The montages will be a '4 × 1 ring set-up', which is the most commonly used HD-tDCS setting. The centre anode electrode is surrounded by four return cathode electrodes. The anode will be placed over the left dorsal lateral prefrontal cortex. Conductive electrode gel will be applied on the scalp at all designated electrode stimulation areas. A cap appropriate for each participants' head size will be used to ensure that the electrodes are secured in place. Impedance checks will be performed using the Starstim software before each treatment session.
Study NCT05643404 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardioghaphy
Description: Doppler echocardiogram examinations were performed under resting conditions using 2-dimensional echocardiography. Left ventricular end-diastolic volume and left ventricular ejection fraction will be measured according to the European Society of Echocardiography
Study NCT05276531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: subcutaneous progesterone
Description: clinical pregnancy rates
Study NCT05276531 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vaginal progesterone
Description: clinical pregnancy rates
Study NCT04089046 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TEAM-UP for Teens
Description: TEAM-UP for Teens pairs school-based directly observed therapy (DOT) of daily preventive asthma medications with specialist care and ongoing self-management support using live, real-time telemedicine through school.
Study NCT04089046 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Care (EC)
Description: Teens in the EC group will receive a symptom assessment and asthma education materials at baseline, and their PCPs will be contacted by facsimile or email to recommend DOT of preventive asthma medication through school as well as referral to an asthma specialist. Systematic reminders will be sent to the family and PCPs to schedule recommended healthcare visits and consider specialist referral at the same intervals as the TEAM-UP group's virtual visits.
Study NCT06273462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palmitoylethanolamide 600mg twice a day
Description: 600mg palmitoylethanolamide twice a day
Study NCT06273462 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: visually identical placebo capsule
Study NCT05652530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chimeric Antigen Receptor NK Cell Injection Targeting BCMA (BCMA CAR-NK)
Description: This product is allogeneic NK cells which are cryopreserved after in vitro CAR genetic modification and scale-up manufacturing. Subjects are enrolled and treated with lymphocyte clearance chemotherapy (including pre-clearance evaluation), pre-infusion evaluation and BCMA CAR-NK cells infusion.
Study NCT05322863 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: High-definition Transcranial Direct Current Stimulation
Description: The HD-tDCS will be administered by the program device called Starstim (Neuroelectrics). All participants will receive the treatment by using the same model of device. The HD-tDCS device can be portable and controlled wirelessly via computer software developed by the manufacturer. The montages will be a '4 × 1 ring set-up', which is the most commonly used HD-tDCS setting. The centre anode electrode is surrounded by four return cathode electrodes. The anode will be placed over the left dorsal lateral prefrontal cortex. Conductive electrode gel will be applied on the scalp at all designated electrode stimulation areas. A cap appropriate for each participants' head size will be used to ensure that the electrodes are secured in place. Impedance checks will be performed using the Starstim software before each treatment session.
Study NCT05994794 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Alpha-GPC, Creatine and Ashwagandha (Sensoril®)
Description: Other Ingredients: Microcrystalline Cellulose, Rice Fiber, Maltodextrin, Silica, Vegetable Stearate
Study NCT05994794 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Microcrystalline Cellulose
Study NCT01449357 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zalutumumab
Description: IV infusion, 16mg/kg on weekly basis until DP
Study NCT05302739 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Facial cooling
Description: 30 s of water mist sprayed onto the face during breaks in a simulated fencing competition
Study NCT05671952 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Application of integrated intervention system programs
Description: Application of integrated intervention system programs
Study NCT06642090 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational intervention for patients undergoing hemodialysis in Morocco
Description: This is the first educational intervention in Morocco to improve the knowledge, self-care, and biological characteristics of patients undergoing hemodialysis.
Study NCT06198400 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Perioperative assessment of the perfusion of post-resection pancreatic remnant using indocyanine green-VerDye
Description: The adequacy of the vascular supply of the post resection pancreatic remnant after pancreatic neck division will be evaluated using ICG detector. Indocyanine green fluorescence product -Verdye™ will be intravenously applied. The application of the substance will be performed according to the current consensus statement and recommendation
Study NCT06639685 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: MR Fingerprinting and ASL
Study NCT05888922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minoxidil Tablets
Description: The clinical trial will use a block randomization scheme to assign those eligible patients to one of the three arms of the study treatment on a 2:2:1 ratio. All patients will be given a kit with oral tablets (active/placebo) 1 tablet to be taken once a day and a topical solution (active comparator/vehicle) to be applied 1 ml twice daily.
Study NCT05888922 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Minoxidil Topical
Description: The clinical trial will use a block randomization scheme to assign those eligible patients to one of the three arms of the study treatment on a 2:2:1 ratio. All patients will be given a kit with oral tablets (active/placebo) 1 tablet to be taken once a day and a topical solution (active comparator/vehicle) to be applied 1 ml twice daily.
Study NCT05888922 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo oral tablet
Description: The clinical trial will use a block randomization scheme to assign those eligible patients to one of the three arms of the study treatment on a 2:2:1 ratio. All patients will be given a kit with oral tablets (active/placebo) 1 tablet to be taken once a day and a topical solution (active comparator/vehicle) to be applied 1 ml twice daily.
Study NCT05888922 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: The clinical trial will use a block randomization scheme to assign those eligible patients to one of the three arms of the study treatment on a 2:2:1 ratio. All patients will be given a kit with oral tablets (active/placebo) 1 tablet to be taken once a day and a topical solution (active comparator/vehicle) to be applied 1 ml twice daily.
Study NCT05888922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vehicle solution
Description: The clinical trial will use a block randomization scheme to assign those eligible patients to one of the three arms of the study treatment on a 2:2:1 ratio. All patients will be given a kit with oral tablets (active/placebo) 1 tablet to be taken once a day and a topical solution (active comparator/vehicle) to be applied 1 ml twice daily.
Study NCT05888922 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle solution
Description: The clinical trial will use a block randomization scheme to assign those eligible patients to one of the three arms of the study treatment on a 2:2:1 ratio. All patients will be given a kit with oral tablets (active/placebo) 1 tablet to be taken once a day and a topical solution (active comparator/vehicle) to be applied 1 ml twice daily.
Study NCT06563986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Systemic treatment (FTD-TPI and bevacizumab)
Description: Systemic treatment (FTD-TPI and bevacizumab) administration is according to standard clinical practice. Each treatment cycle will be 28 days in duration.~One treatment cycle consists of the following:~* Days 1-5: oral intake of FTD-TPI and bevacizumab IV infusion on day 1~* Days 8-12: oral intake of FTD-TPI~* Day 15: bevacizumab IV infusion~Bevacizumab 5.0mg/kg i.v. is repeated every 2 weeks. If toxicity occurs, dose modifications and dose delays should be administered and applied according to standard practice.
Study NCT06563986 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radioembolization with 166-Ho microspheres
Description: Individualized 166Ho radioembolization will be performed via a catheter during angiography. Before the treatment, a scout procedure will be performed to determine individualized 166Ho dose of the treatment. Dosimetry-based treatment planning will be individualized using Q- Suite software.~In case of bilateral disease, patients will be treated in two procedures to each hemi-liver, separated by 1 month. Before the first procedure, a scout procedure will be performed in which the individualized 166Ho dose of the first and second procedure will be calculated.
Study NCT06565013 — intervention group
Intervention type: DRUG
Intervention: Cabenuva 600/900
Description: Participants will switch to Cabenuva at baseline. The visit schedule, the product administration and the clinical follow-up will be done according to standard of care.
Study NCT06565013 — intervention group
Intervention type: OTHER
Intervention: Self administered questionnaires
Description: Questionnaires on treatment satisfaction (HIVTSQs), quality of life (WHOQoL-HIV-BREF) and drug use assessment (DEBA-D) will be administered at baseline, M5 and M11
Study NCT06565013 — intervention group
Intervention type: OTHER
Intervention: Semi-directed interview
Description: At baseline and M11, participants will conduct a semi-directed interview about the perception of their HIV treatment and the global care they receive as a person living with HIV who is practicing chemsex.
Study NCT06584799 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Micronized purified flavonoid fraction
Description: Micronized purified flavonoid fraction (MPFF) 1000. Active substance: micronized purified flavonoid fraction (diosmin+flavonoids expressed as hesperidin). MPFF is a venotonic agent that also has angioprotective properties. It reduces venous distensibility and blood stasis, capillary permeability, and increases capillary resistance.~MOFF 1000 dosing regimen is 1000 mg once daily for 2 months.
Study NCT06584799 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diosmin 600
Description: Venotonic action: the drug reduces venous distensibility, increases venous tone, reduces blood stasis, and enhances the vasoconstrictor effect of epinephrine and norepinephrine. The optimal daily dose of diosmin 600 for obtaining venotonic effect is 600 mg.
Study NCT05416099 — intervention group
Intervention type: PROCEDURE
Intervention: laser
Description: grid vs micropulse laser
Study NCT03878953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhPTH(1-84)
Description: Participants will receive a SC injection of initial dose of 50 mcg of rhPTH(1-84) once daily (QD) in the thigh (alternate thigh every day). If albumin-corrected serum calcium (ACSC; \[mg/dL\] = serum calcium \[mg/dL\] +0.8\*\[4-serum albumin (g/dL)\]) is >2.25 mmol/L (>9.0 mg/dL), a starting dose of 25 mcg will be considered. At 4 week intervals the rhPTH(1-84) dose may be increased in 25 mcg increments to a maximal dose of 100 mcg SC QD. At any time during the study as needed for safety reasons, rhPTH(1-84) doses may be decreased in 25 mcg decrements to a minimum of 25 mcg QD. If the ACSC is >2.97 mmol/L (>11.9 mg/dL), then the investigational product should be stopped until the calcium level is corrected.
Study NCT05086809 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Device A
Description: Participant wear Device A and evaluate the performance of the device.
Study NCT05086809 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Device B
Description: Participant wear Device B and evaluate the performance of the device.
Study NCT05593952 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dual task
Description: exercise with dual task + usual treatment
Study NCT05593952 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Single task
Description: exercise without dual task + usual treatment.
Study NCT05082649 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Face to Face Exercise
Description: Face to face (in clinic) progressive spinal stabilization exercises.
Study NCT05082649 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation
Description: Remotely (with video) progressive spinal stabilization exercises.
Study NCT06173570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0780
Description: AZD0780 administered orally, once daily for 12 weeks
Study NCT06173570 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered orally, once daily for 12 weeks
Study NCT04688047 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nursing care based on the transtheoretical model
Description: Nursing care consists of urinary incontinence training, motivational interview and telephone/mail counseling processes.
Study NCT05436132 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VR and AR oral healthcare curriculum training
Description: HCWs in the VR/AR group received 2.5 hours VR and AR oral healthcare curriculum training. VR oral care training system was training the standard oral healthcare procedure for different physical and oral conditions in elderly people.AR oral care training system was training for the manual Bass brushing technique.
Study NCT05436132 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: traditional teaching methods oral healthcare curriculum
Description: HCWs in the control group received 2.5 hours traditional teaching methods of oral healthcare curriculum training.
Study NCT04282239 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PECS2 block
Description: Superficial peripheral nerve block placed at the interfascial plane between the pectoralis major and minor muscles and the plane between the pectoralis minor and serrates anterior muscles. Targeted nerves include the lateral and medial pectoral nerves in addition to the long thoracic nerve, thoracodorsal, and thoracic intercostal nerves from T2 to T6.
Study NCT04282239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.5% Injectable Solution
Description: 15 mL on each side of anterior chest for a total of 30mL
Study NCT04282239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Epinephrine
Description: 10 mL on each side of anterior chest for a total of 20mL
Study NCT04282239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.004 MG/ML
Description: 10 mL
Study NCT05945810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLL-018 extended-release tablet
Description: 50mg TLL-018 extended-release tablet QD